Anesthetics, Anesthetics, Intravenous, Cardiopulmonary Bypass, Pharmacology
Conditions
Keywords
remifentanil
Brief summary
Target controlled infusion with remifentanil is widely used during cardiac surgery, wich is performed using the Minto model. It was derived from patients undergoing general surgery. However, pharmacokinetics of remifentanil can be changed during cardiopulmonary bypass. The investigators tested whether Minto model for target controlled infusion produces constant plasma remifentanil concentration during the cardiac surgery.
Interventions
DRUGRemiva
Target controlled infusion of remifentanil (generic drug, Remiva™)
DRUGUltiva
Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients with the ASA class I\ III undergoing elective cardiac surgery using cardiopulmonary bypass
Exclusion criteria
* Patients not using target controlled infusion during the operation * Patients with drug/substance abuse * Patients using analgesics before this study starts * Pregnant women * Patients who rejected study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median prediction error | during CPB |
Secondary
| Measure | Time frame |
|---|---|
| changes of measured total remifentanil concentration | 1 hour after anesthesia induction, 30/60/90 min after the beginning of cardiopulmonary bypass, 1 hour after the end of cardiopulmonary bypass |
| Median absolute prediction error | during CPB |
Countries
South Korea
Outcome results
None listed